Published in

Wiley Open Access, Clinical Case Reports, 6(3), p. 499-503, 2015

DOI: 10.1002/ccr3.281

Links

Tools

Export citation

Search in Google Scholar

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms

Journal article published in 2015 by Mads Emil Bj, Mads Emil Bjørn, Hans Carl Hasselbalch
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The inflammation-mediated comorbidities in myelofibrosis (MF) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK1-2 inhibitors in MF-patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation-mediated comorbidities.